|Recombinant Human TNFα protein (Catalog#10602-HNAE)|
|0.2 μm filtered solution in PBS|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human Tumor necrosis factor-alpha (rhTNFα; Catalog#10602-HNAE; Val 77-Leu 233; NP_000585.2). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.|
ELISA: 0.5-1.0 μg/mL
This antibody can be used at 0.5-1.0 μg/mL with the appropriate secondary reagents to detect Human TNFα. The detection limit for Human TNFα is approximately 0.6 ng/well.
ELISA(Cap): 0.5-4 µg/ml
This antibody will detect Human TNF-alpha / TNFA / TNFSF2 in ELISA pair set (Catalog: # SEKA10602). In a sandwich ELISA, it can be used as capture antibody when paired with (Catalog: # 10602-MM08).
FCM: 0.5-2 μg/Test
Tumor necrosis factor alpha (TNF-alpha), also known as TNF, TNFA or TNFSF2, is the prototypic cytokine of the TNF superfamily, and is a multifunctional molecule involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. Two receptors, TNF-R1 (TNF receptor type 1; CD120a; p55/60) and TNF-R2 (TNF receptor type 2; CD120b; p75/80), bind to TNF-alpha. TNF-alpha protein is produced mainly by macrophages, and large amounts of this cytokine are released in response to lipopolysaccharide, other bacterial products, and Interleukin-1 (IL-1). TNF-alpha is involved in fighting against the tumorigenesis, thus, is regarded as a molecular insight in cancer treatment.